Your browser doesn't support javascript.
loading
IL3 Has a Detrimental Effect on Hematopoietic Stem Cell Self-Renewal in Transplantation Settings.
Tajer, Parisa; Canté-Barrett, Kirsten; Naber, Brigitta A E; Vloemans, Sandra A; van Eggermond, Marja C J A; van der Hoorn, Marie-Louise; Pike-Overzet, Karin; Staal, Frank J T.
Afiliação
  • Tajer P; Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Canté-Barrett K; Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Naber BAE; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Vloemans SA; Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • van Eggermond MCJA; Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • van der Hoorn ML; Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Pike-Overzet K; Department of Obstetrics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Staal FJT; Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Int J Mol Sci ; 23(21)2022 Oct 22.
Article em En | MEDLINE | ID: mdl-36361533
ABSTRACT
The ex vivo expansion and maintenance of long-term hematopoietic stem cells (LT-HSC) is crucial for stem cell-based gene therapy. A combination of stem cell factor (SCF), thrombopoietin (TPO), FLT3 ligand (FLT3) and interleukin 3 (IL3) cytokines has been commonly used in clinical settings for the expansion of CD34+ from different sources, prior to transplantation. To assess the effect of IL3 on repopulating capacity of cultured CD34+ cells, we employed the commonly used combination of STF, TPO and FILT3 with or without IL3. Expanded cells were transplanted into NSG mice, followed by secondary transplantation. Overall, this study shows that IL3 leads to lower human cell engraftment and repopulating capacity in NSG mice, suggesting a negative effect of IL3 on HSC self-renewal. We, therefore, recommend omitting IL3 from HSC-based gene therapy protocols.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interleucina-3 / Transplante de Células-Tronco Hematopoéticas Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interleucina-3 / Transplante de Células-Tronco Hematopoéticas Idioma: En Ano de publicação: 2022 Tipo de documento: Article